Certificate under reg 74(5) of SEBI(DP) regulations, 2018
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Concord Drugs Ltd has submitted a quarterly compliance certificate from its Registrar and Share Transfer Agent (RTA), Aarthi Consultants Private Limited, for the quarter ended 30 June 2025. The certificate confirms that the RTA has complied with Regulation 74(5) of SEBI (DP) Regulations, 2018 within 15 days of receiving share certificates from the depository participants. Specifically, the RTA has mutilated and cancelled the physical certificates received and updated the depository's name as the registered owner in its records for the period 1 April 2025 to 30 June 2025. This is filed with BSE (Scrip Code: 538965) as a routine regulatory disclosure. The certificate was signed by the company's Managing Director, Nagi Reddy Seelam.
This is a routine quarterly compliance filing with no material impact on the business or stock price. It merely confirms that physical share certificates submitted for dematerialization have been properly processed and cancelled during the April-June 2025 quarter.